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ABSTRACT 
 
Purpose: Transurethral incision of the prostate gland (TUIP) is perceived as a less morbid surgical 
alternative to standard transurethral resection of the prostate gland (TURP) for treatment of 
symptomatic mild to moderate benign prostate enlargement (BPE). We aimed to evaluate comparative 
clinical effectiveness of the two procedures. 
Methods: Systematic review and meta-analysis of short and long-term data from randomised 
controlled trials comparing TUIP with TURP. 
Results: This review considered data from 795 randomised participants across 10 RCTs of moderate to 
poor quality eight of which stated an upper limit for prostate size. No difference in the degree of 
symptomatic improvement was seen between the two procedures. Improvement in peak urine flow rate 
was lower for TUIP compared to TURP whilst the rate of blood transfusion and TUR syndrome was 
higher after TURP. Urinary retention, urinary tract infection, strictures and incontinence did not differ 
between the two approaches, although clinically important differences could not be ruled out. TUIP 
was associated with a shorter duration of operation and length of hospital stay but a higher re-operation 
rate. 
Conclusion: TUIP and TURP appear to offer equivalent symptomatic improvement for men with mild 
to moderate BPE.  Choosing TUIP involves a trade-off between the lower risk of peri-operative 
morbidity and the higher risk of subsequent re-operation. 
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INTRODUCTION 
Lower urinary tract symptoms (LUTS) presumed due to clinical benign prostate enlargement (BPE) are 
common, affecting up to 40% of men over 70 years of age [1]. Long-term studies show the progressive 
nature of clinical BPE related to hyperplasia of the stromal and urothelial components of the gland with 
both International Prostate Symptom Score (IPSS) and prostate volume increasing with age [2].  
 
The aim of treating BPE is to improve bothersome LUTS and associated quality of life, and to prevent 
or lessen complications such as urinary retention, infection and deteriorating renal function. Treatment 
options range from self-monitoring of mild symptoms to drugs and on to surgical intervention. 
 
Surgical treatment of clinical BPE has evolved since the work of Guthrie in the 19th century [3] with 
the development of various endoscopic techniques each with specific advantages and disadvantages; 
two such techniques are transurethral resection of prostate (TURP) involving diathermy resection of the 
inner component of the prostate gland, and transurethral incision of prostate (TUIP) involving 
longitudinal incision of the prostate gland, allowing widening of the bladder neck and prostatic urethra 
without removal of prostate tissue.  Adverse effects associated with TURP such as bleeding, 
cardiovascular imbalance and sexual dysfunction have driven the search for less invasive alternatives 
[4].  TUIP has been trialled as a less morbid alternative for men with prostate glands < 30 ml in size, 
with the suggested advantage of less bleeding and sexual dysfunction [5].  As part of a wide ranging 
review of surgical treatments for BPE commissioned by the United Kingdom National Institute for 
Health Research [6], we aimed to evaluate the comparative clinical effectiveness of TUIP against 
TURP by means of a systematic review of available randomised controlled trials (RCTs). 
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METHODS 
Searching for the evidence  
Highly sensitive electronic searches, using a combination of database-specific subject headings and text 
terms, were developed to identify published and unpublished reports of relevant RCTs evaluating the 
effectiveness of TUIP and TURP for BPE. Bibliographic databases searched including Medline, 
Embase, Biosis, Science Citation Index, The Cochrane Library, and trials registers. All searches were 
carried out during March 2006.  Recent conference proceedings (European Association of Urology, 
American Urological Association and the British Association of Urological Surgeons) for the years 
2002-5 were also screened. Searches were not restricted by publication year or language. Reference 
lists of all included studies were scanned to identify additional potentially relevant studies.  Full details 
of the search strategies used have been published [6] or are available from the authors. The titles and 
abstracts of all papers identified by the search strategy were screened and full-text copies of all 
potentially relevant studies obtained. 
 
Selection and study characteristics 
Individual RCTs of TUIP compared to TURP for BPE were included. Trials reporting men without a 
clinical diagnosis of BPE were excluded as well as comparisons against conservative management. The 
pre-specified outcomes are listed in Table 1. Symptom scores measured by the IPSS, the American 
Urological Association Symptom Index (AUA), or Madsen-Iversen score were eligible. IPSS and AUA 
scores were considered equivalent and therefore trials using these instruments were combined. The 
IPSS/AUA symptom questionnaire asks men to rate four voiding symptoms (poor stream, intermittent 
flow, straining, incomplete emptying) and three storage symptoms (frequency, nocturia, urgency) on a 
scale from 0 (not present) to 5 (severe) to give a total score ranging from 0 to 35, with symptom 
severity defined as: mild (0-7), moderate (8-19) or severe (20-35). With Madsen-Iversen scores, 
patients are rated in terms of the quality of their urinary stream, straining to void, hesitancy, 
intermittency, bladder emptying, stress incontinence or post void dribbling, urgency, frequency, and 
nocturia on a scale from 0 to 4 to give a total score ranging from 0 to 27, with symptom severity 
defined as: mild (<10), moderate (10-20) or severe (>20). All reports of pre-specified complications 
were considered regardless of their timing. Bladder neck stenosis and urethral stricture were combined 
since separate reporting of these complications was inconsistent. 
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Quality assessment strategy 
Two reviewers, working independently, assessed the methodological quality of included studies using 
an assessment tool drawing on the schema suggested by the NHS Centre for Reviews and 
Dissemination [7-9]. 
 
Data extraction strategy 
The titles and abstracts of all papers identified by the search strategy were screened. Two reviewers 
independently assessed full-text copies of all potentially relevant studies and extracted data from the 
included studies. The two reviewers recorded details of methodology, interventions, participants’ 
characteristics and outcomes on a data extraction form. Those differences that could not be resolved 
through discussion were decided by an arbiter. Reviewers were not blinded to the names of the studies’ 
authors, institutions or sources of the reports. 
 
Data synthesis 
For trials with multiple publications, only the most complete report for each outcome was included 
(Appendix). Meta-analysis was performed by combining dichotomous outcome data using the Mantel-
Haenszel relative risk (RR) method and for continuous outcome data using the inverse variance 
weighted mean difference (WMD) method and 95% confidence intervals. Fixed effects models were 
used for all analyses except peak flow and symptom score where random effects were used due to 
variability in reporting and statistical heterogeneity (assessed using I- and Chi-squared tests). Other 
possible reasons for heterogeneity were explored using sensitivity analyses. The meta-analyses were 
conducted using the standard Cochrane software RevMan 4.2.8. 
 
Due to the lack of uniformity of the data presented by many studies, a qualitative review looking for 
consistency between studies was also performed. This was supplemented, where appropriate by 
considering the consistency in the direction of effects using the sign-test. 
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RESULTS 
We assessed full-text copies of 621 published articles concerning TURP and TUIP to yield 10 RCTs 
meeting inclusion criteria for the review which were published in 14 reports and described outcome in 
795 men recruited between 1985 and 1991, 392 of whom underwent TUIP and 403 TURP [10-22]. An 
upper limit of prostate size was explicitly stated as an entry criterion for eight studies with five < 30 ml 
and three < 60 ml.  
 
Quality and characteristics of available evidence 
All RCTs were of similar poor to moderate quality, with the majority failing to provide details about 
randomisation, treatment allocation concealment and whether the analyses included an intention to treat 
analysis (Table 2). The included data allowed comparison of 10 relevant outcomes involving 795 
participants. Included studies varied in relation to settings and baseline characteristics of the patients, 
such as severity of the disease and prostate size (Table 3).   
 
Assessment of effectiveness 
Symptom scores 
Five [11,13,15,16] studies provided information on symptom scores for patients at 12 months after 
treatment. Four of these reported change in Madsen-Iversen scores, one reported IPSS scores [18]. 
Losses to follow-up were high in nearly all studies reporting 12 months follow-up. No clear pattern 
emerged (sign test, p < 0.375): three favoured TURP, one TUIP, and one showed no difference. Only 
two studies presented data in a form suitable to allow meta-analysis, which showed that the direction of 
effect was not consistent across the studies (IPSS: mean difference (MD) -1.00, 95% CI -1.73 to -0.27, 
p = 0.007; Madsen-Iversen: MD 0.34, 95% CI -1.55 to 2.23). 
 
Peak Urine Flow rate 
All five studies [11,13,14,16,17] that provided information on the mean or median peak urine flow rate 
for patients 12 months after surgery reported lower (worse) mean or median peak urine flow rate 
following TUIP (sign test p < 0.03). Synthesis of suitable data [16] showed that peak urine flow rate 
was lower but this did not reach statistical significance (MD -2.71, 95% CI -5.77 to 0.35, p = 0.08). 
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Morbidity  
Seven RCTs [11-14,17,19,20] provided information on need for blood transfusion. There were fewer 
blood transfusions following TUIP in all except one trial [12] reporting no transfusions in either group 
(Figure 1: 3/266 (11%) versus 77/272 (28%) RR = 0.06, 95% CI 0.03 to 0.16, p < 0.001). 
 
TUR syndrome information was reported in two studies [17,19]. No cases of a TUR syndrome were 
recorded in patients undergoing TUIP. Conversely, 6.4% of the patients (all in one trial) allocated to 
TURP had TUR syndrome [17] (Figure 1: 0/139 versus 7/140, RR = 0.07, 95% CI 0.00 to 1.15, p = 
0.06). 
 
Meta-analysis of studies reporting data on urinary retention [13,14,15,19], urinary tract infection [17], 
stricture [11,12,14,15,17,19], and incontinence [14,17,19] showed that there were no statistically 
significant differences between TUIP and TURP (Figure 1). Clinically important differences could not 
be ruled-out as the size and direction of effect varied across studies and the confidence intervals were 
wide. Also, definitions of strictures, incontinence and length of follow-up varied across studies. 
 
Seven studies [11,12,15-17,21] reported sexual dysfunction information. The risk of retrograde 
ejaculation was lower for men following TUIP than after TURP (Figure 2: 46/195 (23.5%) versus 
88/189 (46.5%) RR 0.51, 95% CI 0.38 to 0.68, p < 0.001), whereas, there was no statistically 
significant difference in terms of erectile dysfunction between the two groups (Figure 2: 4/119 (3.4% 
versus 6/103 (5.8%), RR 0.61, 95% CI 0.17 to 2.20, p = 0.45). 
 
Descriptors of care 
Seven studies [11-15,17,19]  provided information on duration of operation and another seven studies 
[11,12,14,15,17,19,20] detailed length of hospital stay. In all studies duration of operation was shorter 
in the TUIP group (sign test p < 0.01). Two studies [12, 19] reported data suitable for synthesis and the 
average duration of TUIP was 18.9 minutes shorter than TURP (Figure 3: 95% CI -24.13 to -13.67, p < 
0.001). Meta-analysis of two studies [12, 19] showed that the average length of hospital stay was also 
significantly shorter following TUIP (Figure 3: WMD -2.26, 95% CI -3.81 to -0.71, p = 0.004). Meta-
analysis of six trials showed that the need for re-operation was more common after TUIP than after 
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TURP [10,11,13-16] (Figure 3: 36/196 (18.4% versus 14/195 (7.2%), RR 2.40, 95% CI 1.37 to 4.21, p 
< 0.01). It should be noted that differences between studies in timing and completeness of follow-up 
may have introduced bias and we have therefore tabulated data used for this analysis (Table 4).   
 
DISCUSSION 
Our search strategy identified 621 articles concerning TURP and TUIP of which 14 reported data from 
10 RCTs.  The included subjects had mainly mild to moderate BPE. No clear evidence of superiority 
emerged on meta-analysis regarding our primary outcome of improvement in symptom score at 12 
months but analysis was hampered by high drop-out rates and by only two trials reporting data in 
suitable format.  Consideration of a further four trials was supportive of this finding with no consistent 
pattern of relative effectiveness.  A single report found that equivalence of symptomatic benefit 
persisted for up to five years [13].  In contrast, TURP was clearly superior in terms of urodynamic 
improvement with a consistent and statistically significant greater increase in peak urinary flow rate 
[10-17]. The equivalence of patient-reported outcome suggests that men with mild to moderate of BPE 
would be content with the symptom improvement gained with TUIP.  Clinicians however are likely to 
have some concerns regarding the inferior efficacy of the procedure in correcting bladder outlet 
obstruction. 
 
To balance this concern, TUIP does demonstrate further advantages in terms of reduced co-morbidity 
and hospitalisation.  Blood transfusion rates are used as a proxy measure of blood loss and were 
significantly lower with TUIP.  It should be noted that subjects recruited for the included trials were all 
treated prior to 1991.  Equipment, peri-operative care and standards of training for urologists 
performing TURP have all improved over the past 20 years reflected in current transfusion rates of < 
2.5% [23].  Avoidance of TUR syndrome appears to be an advantage of TUIP since although a rare 
complication, it can be life-threatening [17,19]; it should be noted however that prostate size was not 
explicitly reported by these studies. TUIP did not show advantage in terms of reducing the risk of 
longer term adverse effects such as urinary incontinence, erectile dysfunction or stricture formation 
although reporting of these events was inconsistent and important differences could have been missed.  
Meta-analysis did however confirm lower rates of ejaculatory dysfunction following TUIP with a 50% 
risk reduction. This is likely to be an important issue for sexually active men with isolated bladder neck 
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hypertrophy, but this adverse effect does not seem to be bothersome for most men undergoing surgery 
for BPE [24].   
 
In terms of treatment cost, TUIP shows benefit in terms of reducing operating time and hospital stay 
but this must be balanced by increased expenditure due to the higher rate of re-operation in the longer 
term.  Ideally these variables would need inclusion with effectiveness data in a formal analysis of cost-
effectiveness to determine any overall advantage for TUIP.   
 
In broad terms, results from our systematic review and meta-analysis are in agreement with those 
published in a previous study by Yang and colleagues [25]. Our review identified two additional 
studies [18,20] and we were unable to include unpublished data that Yang and colleagues obtained 
from trial report Authors, but these differences in included data did not affect key findings such as 
equivalence of symptomatic improvement and superior urodynamic outcome for TURP.  In contrast to 
Yang et al. [25], we found a significantly higher risk of re-operation following TUIP which, if truly 
reflective of outcome, would have an important bearing on cost-effectiveness.  Our decision to exclude 
data from two trials [12,19] on pre-stated methodological criteria together with differences in statistical 
methodology used for data synthesis may have contributed to this differing finding, and illustrate that 
assumptions made during systematic review can change conclusions. Increased re-operation rate 
following TUIP is a factor that men deciding between the two techniques will have to trade off against 
decreased risk of adverse effects.  For these reasons we feel that the present systematic review does 
provide a value to the urological community by reinforcing the key findings of Yang and colleagues 
using a different methodology and by clarifying potentially important differences such as re-operation 
rates.  This will be helpful for those charged with guideline development and makers of health policy.  
 
We used current recommended methodology for this review which included quality assessment of 
included trials.  As has been previously noted [25] trial quality in this area is variable although we do 
acknowledge the procedural difficulties in conducting and reporting comparative trials of surgical 
treatments.  The majority of studies were conducted and reported prior to the formulation of 
CONSORT guidelines which may partly explain the wide variation in reporting practice and in 
particular the fact that results concerning primary outcomes were generally reported in a format 
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unsuited to meta-analysis. A common failing with such trials is loss to follow-up which compromises 
the certainty of comparative analysis of long-term outcome, a key measure in the study of treatment of 
chronic and recurring health problems such as BPE.  
 
Conclusion 
This systematic review of available RCTs comparing TUIP and TURP for treatment of mild-moderate 
BPE has shown TUIP to give equivalent symptomatic improvement accompanied by a reduction in risk 
of adverse effects. Approximately 2,500 such procedures are carried out annually in England compared 
to about 25,000 TURP suggesting that it continues to be under-utilised [26]. Ideally an adequately 
powered, multi-centre RCT comparing TUIP and TURP should be performed but this is unlikely to be 
funded due to the advancement of other technologies such as laser energy to more safely ablate the 
prostate together with the long follow-up required to assess reoperation rate.  It is possible however that 
the procedure could be included in long-term ‘tracker’ trials linked to patient or clinician preference to 
better determine longer term clinical effectiveness and cost-effectiveness. 
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